Ionis Posts $243 Million in Q3 Revenue and $0.66 Per-Share Loss

John Kim

1 min read

Add as a preferred source on Google

Ionis Posts $243 Million in Q3 Revenue and $0.66 Per-Share Loss

The reporting period ended Sept. 30, 2026.

By John Kim

Published Nov 10, 2026, 2:18 AM EST

An ivory capsule rests on one pan of a compact brass balance scale / TokenPost.ai

Ionis Pharmaceuticals recorded $243 million in revenue and a net loss per share of $0.66 under generally accepted accounting principles (GAAP) for Q3 2026, which ended Sept. 30.

GAAP refers to the accounting rules used to prepare financial statements.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.